Business context and reporting period
Labcorp Holdings’ Form 10-K covers the fiscal year ended December 31, 2023. Labcorp provides clinical diagnostics and biopharma laboratory services through Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS); the filing reports annual results, not a separate fourth-quarter financial summary. Fortrea’s clinical development and commercialization services business was spun off on June 30, 2023, and is presented as discontinued operations for all periods shown.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Continuing-operations revenue | $12,161.6 million | $11,863.9 million |
| Gross profit | $3,364.9 million | $3,708.9 million |
| Operating income | $725.6 million | $1,436.5 million |
| Earnings from continuing operations | $380.4 million | $1,003.5 million |
| Diluted EPS from continuing operations | $4.33 | $10.94 |
| Continuing-operations operating cash flow | $1,202.3 million | $1,764.8 million |
- Revenue increased 2.5%, reflecting acquisitions net of divestitures (+1.7%), organic growth (+0.6%) and favorable currency translation (+0.2%). Organic Base Business growth of 8.7% was partly offset by an 8.1% decline in COVID-19 testing.
- Gross margin fell to approximately 27.7% from 31.3%; operating margin declined to approximately 6.0% from 12.1%. Cost of revenues rose 7.9% and SG&A rose 14.7%.
- Net earnings attributable to Labcorp, including discontinued operations, were $418.0 million versus $1,279.1 million. The 2023 result included $38.8 million of discontinued-operations earnings, versus $277.1 million in 2022.
- Dx revenue was $9,415.1 million, up 2.3%; segment operating income was $1,591.3 million and margin was 16.9%, down from 22.0%. BLS revenue was $2,774.2 million, up 2.9%; segment operating income was $396.3 million and margin was 14.3%, versus 14.4%.
- Cash and cash equivalents were $536.8 million at year-end. Continuing investing cash outflow was $1,146.8 million and continuing financing cash outflow was $1,559.0 million. Capital expenditures were $453.6 million; operating cash flow less capital expenditures was approximately $748.7 million.
- Balance-sheet debt was approximately $5.05 billion, including $999.8 million classified as current. The company had a $1.0 billion revolving credit facility with no balance outstanding at year-end and reported covenant compliance.
Material changes versus the prior comparable period
- Operating income declined 49.5% and continuing-operations diluted EPS fell from $10.94 to $4.33. The filing attributes pressure to lower COVID-19 testing, higher personnel costs, spin-off costs and impairment charges.
- Cash from continuing operations decreased $562.5 million, primarily due to lower COVID-19 testing earnings, spin-off-related items and higher working capital, partly offset by Base Business earnings.
- Labcorp recorded $349.0 million of goodwill and other asset impairments in 2023, principally a $333.6 million goodwill impairment in BLS Early Development, following lower late-year demand and expectations of weaker near-term revenue and profitability. The comparable 2022 impairment total was $261.7 million.
- The Fortrea spin-off changed the company’s portfolio and balance sheet presentation. Fortrea paid Labcorp approximately $1.6 billion in connection with the separation; Labcorp used proceeds in part for $1.0 billion of share repurchases and repayment of $300 million of debt.
Outlook, risks, contingencies and unusual items
- Labcorp expects 2024 capital expenditures of approximately 3.5% of revenue and expects to refinance $1.0 billion of debt coming due in 2024. The filing does not provide a clear numerical revenue or earnings forecast.
- Management highlighted growth priorities in health-system partnerships, specialty diagnostics—including oncology, women’s health, autoimmune disease and neurology—cell and gene therapy, consumer-facing services and international expansion. The company signed or completed six health-system collaboration transactions in 2023.
- Medicare CLFS reductions under PAMA were delayed for 2024. Labcorp expects an additional reduction of approximately $100 million in 2025 across payers affected by the CLFS, absent further delay or reform. The 2024 Medicare Physician Fee Schedule is expected to reduce Dx revenue by approximately 0.7%, or $1.0 million.
- Risks include reimbursement and utilization pressure, customer and contract losses, competition, labor and supply constraints, foreign exchange and interest-rate exposure, cybersecurity and privacy events, and potential new FDA regulation of laboratory-developed tests.
- In a patent case brought by Ravgen, a jury awarded $272 million and the court later awarded $100 million in enhanced damages. Labcorp disputes the result and is pursuing appeals. The filing does not state a final outcome.
- Litigation and inquiries also include claims related to the 2019 AMCA third-party data incident, billing matters, website tracking, and other legal proceedings. The company says it cannot estimate reasonably probable losses for certain matters; review the commitments and contingencies note for status and reserves.
- The company’s tax-free treatment of the Fortrea spin-off depends on tax requirements being met. The filing also describes potential restrictions on certain capital or strategic transactions to preserve tax-free treatment.
Important facts for investors to verify
- How much of reported revenue growth and future performance depends on acquisitions versus organic Base Business growth, and whether COVID-19 testing declines continue.
- Whether Dx margins recover and BLS Early Development demand improves sufficiently to avoid further impairment charges.
- The timing and realized impact of PAMA reimbursement changes, particularly the expected 2025 reduction, and any legislative or regulatory changes.
- Labcorp’s plan and financing cost for refinancing the $1.0 billion due in 2024, alongside cash needs for acquisitions, dividends and repurchases.
- Developments in the Ravgen appeal, AMCA-related litigation and other legal contingencies, as well as any material changes to recorded reserves.
- Progress and compliance costs related to proposed FDA oversight of laboratory-developed tests and privacy or cybersecurity regulation.